6 results match your criteria: "Arrhythmia Institute of the Valley Health System[Affiliation]"
Heart Rhythm
September 2017
Arrhythmia Institute of the Valley Health System, Ridgewood, New Jersey. Electronic address:
J Cardiovasc Electrophysiol
August 2017
Arrhythmia Institute of the Valley Health System, Ridgewood, NJ, USA.
Hypertension
September 2016
From the Departments of Cardiology, Internal Medicine, and Radiology, Isala Hospital, Zwolle, The Netherlands (M.R.d.J., A.A., P.G., J.J.J.S., P.P.H.M.D., J.-E.H., B.A.A.M.v.H., A.R.R.M., A.E.); Center for Innovation and Strategic Collaboration, St Jude Medical, Inc, Irvine, CA (E.O.Y.L.); Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium (A.P.); Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium (A.P.); The Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); and University of Rochester School of Medicine & Dentistry, Arrhythmia Institute of The Valley Health System, New York and Ridgewood, NJ (J.S.S.).
Blood pressure (BP) response to renal denervation (RDN) is highly variable and its effectiveness debated. A procedural end point for RDN may improve consistency of response. The objective of the current analysis was to look for the association between renal nerve stimulation (RNS)-induced BP increase before and after RDN and changes in ambulatory BP monitoring (ABPM) after RDN.
View Article and Find Full Text PDFJ Am Heart Assoc
May 2016
University of Rochester School of Medicine & Dentistry and The Arrhythmia Institute of The Valley Health System, New York, NY University of Rochester School of Medicine & Dentistry and The Arrhythmia Institute of The Valley Health System, Ridgewood, NJ.
Background: The goal of this study was to compare the safety and effectiveness of individual antiembolic interventions in nonvalvular atrial fibrillation (AF): novel oral anticoagulants (NOACs) (apixaban, dabigatran, edoxaban, and rivaroxaban); vitamin K antagonists (VKA); aspirin; and the Watchman device.
Methods And Results: A network meta-analysis of randomized, clinical trials (RCTs) was performed. RCTs that included patients with prosthetic cardiac valves or mitral stenosis, mean or median follow-up <6 months, <200 participants, without published report in English language, and NOAC phase II studies were excluded.
Background: Inadvertent damage to leads for transvenous pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy defibrillators is an important complication associated with generator-replacement procedures. We sought to estimate the incidence and costs associated with transvenous lead damage following cardiac implantable electronic device replacement.
Methods And Results: Using the Truven Health Analytics MarketScan Commercial Research Database, we identified health care claims between 2009 and 2013 for lead damage following generator replacement.
Am J Cardiol
November 2013
Arrhythmia Institute of the Valley Health System, Columbia University College of Physicians & Surgeons, New York, New York and Ridgewood, New Jersey.. Electronic address:
The calculation of the corrected QT interval (QTc) is particularly problematic in patients during atrial fibrillation (AF). The aims of this study were to compare the QTc calculated using Bazett's formula in AF and sinus rhythm (SR) and determine whether alternative methods for QT correction were superior to Bazett's, in an effort to define the optimal method for QT correction in patients with AF. We evaluated consecutive patients with persistent AF admitted for initiation of dofetilide.
View Article and Find Full Text PDF